Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant, non-erosive esophagitis

Table 4 Gastrointestinal symptoms rating scale and 36-item short-form at baseline and 3 mo after endoluminal gastroplication

	Baseline (n = 10)	3 mo (n = 10)
GSRS scale
Overall	2.5 ± 0.8	1.8 ± 0.4a
Acid reflux	3.3 ± 1.5	2.1 ± 0.7a
Abdominal pain	2.7 ± 1.4	1.8 ± 0.9a
Indigestion	2.6 ± 1.0	1.6 ± 0.8a
Diarrhea	1.8 ± 0.9	1.4 ± 0.6
Constipation	2.3 ± 1.3	1.9 ± 1.3
SF-36 scale
Physical functionin	46.6 ± 15.8	53.7 ± 3.8a
Role physical	36.9 ± 20.0	48.7 ± 15.7
Bodily pain	40.5 ± 16.7	52.7 ± 8.3
General health	43.2 ± 7.8	48.8 ± 6.2a
Vitality	42.9 ± 12.7	50.6 ± 6.7
Social functioning	44.0 ± 12.6	47.2 ± 9.9
Role emotional	37.2 ± 19.4	47.7 ± 13.7
Mental health	46.3 ± 11.8	43.3 ± 11.6

^aP < 0.05 vs 3 mo after endoluminal gastroplication by Wilcoxon’s signed rank test. GSRS: Gastrointestinal symptoms rating scale; SF-36: 36-item short-form.